214 related articles for article (PubMed ID: 23640061)
21. A New Risk Index Combining d-Dimer, Fibrinogen, HE4, and CA199 Differentiates Suspecting Endometrial Cancer From Patients With Abnormal Vaginal Bleeding or Discharge.
Ge L; Liu G; Hu K; Huang K; Zhang M; Zhou J; Teng F; Cao J; Dai C; Jia X
Technol Cancer Res Treat; 2020; 19():1533033819901117. PubMed ID: 32167027
[TBL] [Abstract][Full Text] [Related]
22. Is human epididymis protein 4 an effective tool for the differential diagnosis of benign and malignant endometrial tumours?
Minar L; Klabenesova I; Jandakova E; Zlamal F; Bienertova-Vasku J
Eur J Gynaecol Oncol; 2016; 37(5):617-621. PubMed ID: 29786997
[TBL] [Abstract][Full Text] [Related]
23. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.
Moore RG; Brown AK; Miller MC; Badgwell D; Lu Z; Allard WJ; Granai CO; Bast RC; Lu K
Gynecol Oncol; 2008 Aug; 110(2):196-201. PubMed ID: 18495222
[TBL] [Abstract][Full Text] [Related]
24. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
Li QL; Wang CJ; Qi P; Zhang YX
Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
[TBL] [Abstract][Full Text] [Related]
25. Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy.
Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kinalski M; Terlikowski SJ
Adv Med Sci; 2016 Mar; 61(1):23-7. PubMed ID: 26344910
[TBL] [Abstract][Full Text] [Related]
26. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome.
Zanotti L; Bignotti E; Calza S; Bandiera E; Ruggeri G; Galli C; Tognon G; Ragnoli M; Romani C; Tassi RA; Caimi L; Odicino FE; Sartori E; Pecorelli S; Ravaggi A
Clin Chem Lab Med; 2012 Dec; 50(12):2189-98. PubMed ID: 23096757
[TBL] [Abstract][Full Text] [Related]
27. Serum level of HE4 is closely associated with pulmonary adenocarcinoma progression.
Yamashita S; Tokuishi K; Moroga T; Yamamoto S; Ohbo K; Miyahara S; Yoshida Y; Yanagisawa J; Hamatake D; Hiratsuka M; Yoshinaga Y; Shiraishi T; Iwasaki A; Kawahara K
Tumour Biol; 2012 Dec; 33(6):2365-70. PubMed ID: 23001907
[TBL] [Abstract][Full Text] [Related]
28. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.
Li Y; Wang ZC; Luo L; Mu CY; Xu J; Feng Q; Li SB; Gu B; Ma P; Lan T
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):604-610. PubMed ID: 32016961
[TBL] [Abstract][Full Text] [Related]
29. Value of preoperative HE4 as predictor of advanced disease in endometrioid endometrial cancer.
Espiau Romera A; Coronado Martín PJ; Chóliz Ezquerro M; Cuesta Guardiola T; Adiego Calvo I; Baquedano Mainar L
Int J Gynaecol Obstet; 2021 Apr; 153(1):64-70. PubMed ID: 33156532
[TBL] [Abstract][Full Text] [Related]
30. Clinical Significance of Serum HE4, CA125, CA724, and CA19-9 in Patients With Endometrial Cancer.
Bian J; Sun X; Li B; Ming L
Technol Cancer Res Treat; 2017 Aug; 16(4):435-439. PubMed ID: 27562869
[TBL] [Abstract][Full Text] [Related]
31. Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer.
Knific T; Osredkar J; Smrkolj Š; Tonin I; Vouk K; Blejec A; Frković Grazio S; Rižner TL
Gynecol Oncol; 2017 Oct; 147(1):126-132. PubMed ID: 28735628
[TBL] [Abstract][Full Text] [Related]
32. Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: A meta-analysis.
Li J; Wang X; Qu W; Wang J; Jiang SW
Clin Chim Acta; 2019 Jan; 488():215-220. PubMed ID: 30414437
[TBL] [Abstract][Full Text] [Related]
33. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases.
Escudero JM; Auge JM; Filella X; Torne A; Pahisa J; Molina R
Clin Chem; 2011 Nov; 57(11):1534-44. PubMed ID: 21933899
[TBL] [Abstract][Full Text] [Related]
34. HE4 tumor marker concentration in neoplastic peritoneal effusion and in peritoneal fluid associated with benign gynecological diseases.
Chudecka-Głaz A; Cymbaluk-Płoska A; Menkiszak J; Sompolska-Rzechuła A; Byra E; Rzepka-Górska I
J Ovarian Res; 2014 Feb; 7():22. PubMed ID: 24528554
[TBL] [Abstract][Full Text] [Related]
35. Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study.
Capriglione S; Plotti F; Miranda A; Ricciardi R; Scaletta G; Aloisi A; Guzzo F; Montera R; Angioli R
Tumour Biol; 2015 Jun; 36(6):4151-6. PubMed ID: 25577252
[TBL] [Abstract][Full Text] [Related]
36. Preoperative Serum Human Epididymis Protein 4 Levels in Early Stage Endometrial Cancer: A Prospective Study.
Fanfani F; Restaino S; Cicogna S; Petrillo M; Montico M; Perrone E; Radillo O; De Leo R; Ceccarello M; Scambia G; Ricci G
Int J Gynecol Cancer; 2017 Jul; 27(6):1200-1205. PubMed ID: 28557834
[TBL] [Abstract][Full Text] [Related]
37. Role of serum HE4 as a prognostic marker in carcinoma of the ovary.
Lakshmanan M; Kumar V; Chaturvedi A; Misra S; Gupta S; Akhtar N; Rajan S; Jain K; Garg S
Indian J Cancer; 2019; 56(3):216-221. PubMed ID: 31389384
[TBL] [Abstract][Full Text] [Related]
38. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer.
Kalogera E; Scholler N; Powless C; Weaver A; Drapkin R; Li J; Jiang SW; Podratz K; Urban N; Dowdy SC
Gynecol Oncol; 2012 Feb; 124(2):270-5. PubMed ID: 22037318
[TBL] [Abstract][Full Text] [Related]
39. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
[TBL] [Abstract][Full Text] [Related]
40. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.
Simmons AR; Baggerly K; Bast RC
Oncology (Williston Park); 2013 Jun; 27(6):548-56. PubMed ID: 23909069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
